Biotech News

Celcuity To Participate in Upcoming Investor Conferences

Celcuity (CELC)CelcuityCompany update

Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Related news

Celcuity

PAM Pathway Oncology Celcuity develops targeted therapies that inhibit the PI3K-AKT-mTOR signaling network, a pathway frequently involved in treatment resistance and tumor growth. REVTORPYK REVTORPYK, or gedatolisib, is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for certain patients with hormone-receptor-positive, HER2-negative,...

Recent company news

Stock data

Close
56.31 USD
Market cap
4.46B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States